Springworks Therapeutics (SWTX) reported preliminary Q4 net product revenue Monday of $61.5 million.

Analysts polled by FactSet expect $54.6 million.

For all of 2024, the company expects preliminary net product revenue of $172 million.

Analysts polled by FactSet expect $186.4 million.

The company added its preliminary cash, cash equivalents and marketable securities totaled $461.9 million as of Dec. 31, enough to 'fund operations through profitability,' which the company expects achieving in the first half of 2026.

Springworks' shares fell 9% in recent Monday premarket activity.